Delivery Order SPE2DB20D3303-SPE2DB25FA3SP
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,037.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors. This non-set-aside, competitively awarded contract was issued on September 16, 2025, with an ultimate completion date of September 17, 2025, and reflects a firm fixed-price delivery order structure. The product will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency awarded a delivery order valued at $1,213.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of July 29, 2025. The contract, issued on July 28, 2025, employs firm fixed-price pricing and was awarded through open competition with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a...
- The Defense Logistics Agency awarded a $5,864.45 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on September 4, 2025, with completion targeted for September 5, 2025. This non-competitive delivery order represents a firm fixed price transaction under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Emgality is a CGRP monoclonal antibody...
- The Defense Logistics Agency (DLA) awarded a $1,355.21 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injections on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The prime contractor, headquartered in Conshohocken, Pennsylvania, is a major...
- The Defense Logistics Agency awarded a delivery order valued at $2,457.00 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This competitive, firm fixed-price delivery order was executed on August 25, 2025, with an ultimate completion date of August 26, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The contract represents a child order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,037.40 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors under a firm fixed price contract with an ultimate completion date of July 15, 2025. The award, issued on July 14, 2025, represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist used for migraine prevention and treatment,...
- The Defense Logistics Agency awarded a delivery order valued at $1,990.63 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of August 12, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, serves as the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Emgality 120 mg/mL pen injectors, valued at $1,556.10. This is a firm fixed-price delivery order with an ultimate completion date of August 29, 2025, and represents a non-competitive set-aside award. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,309.49 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors on May 20, 2025, with an ultimate completion date of May 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procedures. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Emgality is a migraine prevention medication, reflecting the company's role as a...
- The Defense Logistics Agency awarded a $1,729.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3SPDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,530.62 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of September 17, 2025. This competitive award uses firm fixed pricing with no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical distributor will perform the work at its corporate headquarters in Conshohocken, Pennsylvania. Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for migraine prevention, fulfilling federal medical supply requirements for military and veteran healthcare systems. This delivery order exemplifies AmerisourceBergen's extensive role as a critical pharmaceutical vendor within the federal supply chain, leveraging its comprehensive IDC vehicle to provide specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. The company's capacity to fulfill such orders demonstrates its qualification to meet competitive federal procurement standards and support the Defense Health Agency and other government healthcare providers worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/16/25 |